HCPCS code J3380: Vedolizumab injection billing guide

Key Takeaways

HCPCS code J3380 describes injection, vedolizumab, intravenous, 1 mg – the billing code for Entyvio (vedolizumab) infusions used to treat ulcerative colitis and Crohn’s disease.

A standard 300 mg Entyvio dose requires 300 billable units of J3380 per infusion session – each unit equals 1 mg.

Prior authorization is required by most payers; some commercial payers cap home infusion reimbursement at 13 units per claim, so outpatient and home billing rules differ significantly.

Pabau’s claims management software supports infusion billing workflows, helping practices track drug administration codes, attach correct modifiers, and reduce J3380 claim denials.

HCPCS code J3380 is the Healthcare Common Procedure Coding System Level II code for injection, vedolizumab, intravenous, 1 mg. Maintained by CMS under the category “Drugs Administered Other than Oral Method,” it was added to the HCPCS code set on January 1, 2016.

Vedolizumab is a gut-selective monoclonal antibody marketed by Takeda Pharmaceuticals under the brand name Entyvio, FDA-approved for moderately to severely active ulcerative colitis and Crohn’s disease.

J3380 code description and clinical overview

The unit-based structure of J3380 means a single 300 mg infusion generates a 300-unit claim line. Any documentation error can trigger a denial on every one of those units. This article covers the complete billing workflow: dosage-to-unit conversion, administration codes, ICD-10 pairing, prior authorization requirements, and Medicare reimbursement.

Dosage-to-unit conversion for J3380

One billable unit of J3380 equals 1 mg of vedolizumab. The standard induction and maintenance dose of Entyvio is 300 mg administered intravenously. That means most infusion sessions generate a claim for 300 units of J3380.

The NDC for the Entyvio 300 mg single-use vial should be verified on the vial label or the FDA NDC Directory before billing (the Takeda labeler code is 64764). NDC reporting is required on most commercial and Medicaid claims. For claim submission, bill the 11-digit NDC in the appropriate claim field — CMS requires zero-padding the product or package segment to reach 11 digits, formatted as 5-4-2 (labeler-product-package).

Subcutaneous vedolizumab (Entyvio SC) uses a different billing code — J3285 (Injection, vedolizumab, subcutaneous, 1 mg) — and must not be billed under J3380, which is specific to the intravenous route.

Pabau’s claims management software lets infusion practices configure drug dosage defaults so that every 300 mg vedolizumab infusion automatically populates 300 units on the claim line, reducing the manual calculation errors that generate short-unit denials.

Administration CPT codes billed with J3380

J3380 covers the drug only. The intravenous infusion service must be billed separately using the appropriate administration CPT codes. Most infusion centers billing vedolizumab pair J3380 with one or more of the following:

• CPT 96365 – Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour. Bill this for the first hour of the vedolizumab infusion. This is the primary administration code for a typical 30-minute Entyvio infusion.
• CPT 96366 – IV infusion, each additional hour. Bill this if the infusion extends beyond the first hour (rare for standard vedolizumab, which infuses over approximately 30 minutes).
• CPT 96367 – Additional sequential infusion of a new drug/substance; up to 1 hour. Use when a second drug is administered sequentially in the same encounter.

Under National Correct Coding Initiative (NCCI) edits, CPT 96365 and J3380 are billable together on the same claim. However, if J3380 is administered in a physician office setting, verify that the place of service code and supervising provider credentials align with payer infusion coverage policies. Most payers require the infusion to be performed in a facility or outpatient infusion center for full reimbursement.

Practices offering IV biologic therapy alongside other infusion services can find additional clinical and operational context in this overview of EMR built for IV therapy workflows. Practices also billing self-administered injection supplies alongside infusion services may reference HCPCS code A4211 (supplies for self-administered injections) for guidance on coding ancillary items.

ICD-10 diagnosis codes used with J3380

Every J3380 claim requires a supporting diagnosis code that establishes medical necessity for vedolizumab. The FDA-approved indications for Entyvio are ulcerative colitis and Crohn’s disease, so the paired ICD-10-CM codes come from the K50 and K51 code families.

Select the most specific code available based on clinical documentation. “Unspecified” codes are acceptable when disease site is genuinely not documented, but they increase prior authorization scrutiny. Always code to the highest level of specificity to support medical necessity.

Coders working with colorectal conditions may also reference ICD-10 code C20 (malignant neoplasm of rectum) when patients transition from IBD management to oncology follow-up, and ICD-10 code K60.1 (chronic anal fissure) for comorbid anorectal conditions sometimes documented alongside Crohn’s disease.

Practices using Pabau’s IV therapy EMR software can attach diagnosis codes to patient treatment protocols so that each infusion encounter pulls the correct ICD-10 pair automatically, reducing coder review time per session.

Prior authorization requirements for J3380

Most commercial payers, Medicare Advantage plans, and Medicaid managed care organizations require prior authorization (PA) before reimbursing J3380. The PA requirement reflects vedolizumab’s status as a high-cost specialty biologic, with a list price exceeding $6,000 per 300 mg vial.

Common PA criteria across major payers typically include:

• Confirmed diagnosis of moderately to severely active ulcerative colitis or Crohn’s disease, documented by endoscopic or clinical assessment
• Failure or contraindication to at least one conventional therapy (corticosteroids, immunomodulators) and often one TNF inhibitor
• Prescribing physician is a gastroenterologist or qualified specialist
• Baseline laboratory workup completed (tuberculosis screening, hepatitis B serology)

Home infusion reimbursement rules differ from outpatient infusion billing. Louisiana Medicaid (Humana home infusion benefit) limits reimbursement for J3380 to no more than 13 units per claim under the home infusion benefit. This is a policy-specific cap, not a clinical dosing restriction. Practices billing home infusion for vedolizumab should verify the applicable unit cap with the patient’s specific payer before submission.

Practices building new infusion programs can find payer contracting and clinical setup guidance in this guide to setting up an IV therapy clinic. For practices considering broader strategies to grow their patient base, this article on how to get more patients covers actionable schedule-filling tactics relevant to specialty infusion clinics.

Reduce J3380 claim denials with Pabau

Pabau's claims management tools help infusion centers automate unit calculations, attach the right modifiers, and track prior authorization status so vedolizumab billing runs cleanly from first submission.

Book a demo

Medicare reimbursement for J3380

Medicare Part B reimburses J3380 under the Average Sales Price (ASP) methodology. CMS updates ASP-based drug payment rates quarterly. The reimbursement rate is calculated as ASP plus 6% (ASP + 6%), which represents the drug acquisition cost plus a payment adjustment intended to cover infusion center handling and overhead.

Because payment rates change each quarter, practices should verify the current ASP payment rate using the CMS ASP Drug Pricing files published quarterly at cms.gov/medicare/payment/part-b-drugs. Do not rely on prior-year rates when submitting claims.

Key Medicare billing rules for J3380:

• Bill under the Part B drug benefit, not Part D (which covers self-administered drugs)
• Use place of service code 22 (outpatient hospital) or 11 (physician office) depending on where the infusion occurs
• Modifier JW is required if any drug is wasted from a single-use vial and discarded (report the discarded amount separately)
• Modifier JZ indicates no drug was wasted – use when the full vial is administered
• Traditional Medicare does not require prior authorization for Part B biologics, but Medicare Advantage plans may apply their own PA requirements

Practices managing the full infusion billing cycle can look up HCPCS codes, verify unit billing requirements, and cross-reference fee schedules using the AAPC Codify HCPCS lookup. Related drug-code references such as HCPCS code J3590 (unclassified biologics) also provide useful billing reference data alongside coverage notes.

Staff preparing for infusion program expansion will find workflow and compliance considerations in this guide to IV therapy clinic best practices.

Documentation requirements for J3380 medical necessity

Documentation must establish both the clinical justification for vedolizumab and the specific infusion encounter details. Incomplete records are the leading cause of J3380 denials on post-payment audit.

Each infusion encounter record should include:

• Diagnosis and disease severity: Current disease activity score (e.g., Mayo score for UC, Harvey-Bradshaw index for Crohn’s) documented at the time of infusion authorization
• Prior therapy failure: Record of conventional therapies tried and failed, with dates and outcomes, to support step-therapy PA criteria
• Infusion details: Drug name, dose in mg, route of administration, infusion start and stop time, rate, and lot number
• NDC number: The 11-digit NDC of the specific vial administered, required for commercial and Medicaid claims
• Supervising provider: Name and NPI of the provider overseeing the infusion, required for Part B claims
• Adverse event monitoring: Vital signs pre-, during, and post-infusion, and documentation of any reactions

Practices should keep a standardized infusion record template in the patient chart. Pabau’s digital intake forms can be configured to capture all required infusion documentation fields, creating a structured clinical record that satisfies both prior authorization and audit requirements.

Practices new to infusion documentation can also reference this resource on who can administer IV therapy for clarity on scope-of-practice documentation requirements that may affect claim validity. For practices that also manage chronic-care patients receiving biologic therapy, CPT code 99490 (chronic care management) is a complementary billing code worth reviewing.

Revenue cycle tips to reduce J3380 denials

Vedolizumab claims most commonly fail due to missing or mismatched NDC, wrong unit count, or prior authorization not on file at time of service.

These steps prevent the most common J3380 claim failures:

• Verify PA before every infusion: Confirm authorization number, authorized units, and authorization end date at each visit. PA approvals typically cover a defined number of infusions, not an unlimited ongoing benefit.
• Report the correct unit count: Bill exactly the number of milligrams administered. For a standard 300 mg dose, bill 300 units. Never round up or bill the vial size if a partial dose was administered.
• Attach the NDC on every commercial claim: Missing NDC is one of the top denial reasons for J-code biologics. Use the 11-digit format in the appropriate claim loop (Loop 2410 on 837P).
• Apply JW/JZ modifiers correctly: For Medicare, document and report drug wastage or non-wastage on every claim. Both modifiers are required.
• Appeal denials promptly: J3380 denials for medical necessity are often overturned with supporting clinical documentation. Submit the PA approval letter, the prescribing physician’s clinical notes, and the relevant disease activity score.

Teams managing IV therapy billing workflows can also review the operational guidance in this article on IV therapy intake form documentation for a closer look at how structured intake data reduces downstream billing errors. Practices billing IV infusion hydration services alongside biologic infusions should also review CPT code 96360 (IV hydration billing guide) for guidance on correctly separating hydration and drug-administration claim lines.

Conclusion

Billing J3380 accurately depends on three things: the right unit count per infusion, a paired ICD-10 code that satisfies the payer’s medical necessity criteria, and prior authorization confirmed before the patient arrives. Miss any one of those and the claim fails, often on all 300 units.

Pabau’s claims management tools give infusion centers a structured way to manage J3380 billing: configure drug defaults, attach modifiers, track PA status, and document infusion encounters in one place. To see how Pabau supports infusion and specialty clinic billing workflows, book a demo.

Continue your research

Need a starting point for IV therapy clinic setup? How to open an IV therapy clinic covers licensing, payer contracting, and clinical workflow requirements.

Looking for a broader billing code reference? Coaching CPT codes provides a parallel reference structure for procedure-based billing outside infusion therapy.

Want cleaner claims across infusion visits? IV therapy clinic best practices outlines the clinical recordkeeping standards that support clean claims.

Frequently Asked Questions